Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more

Location: 155 BOVET ROAD, SAN MATEO, CA, UNITED STATES, 94402, San Mateo, CA, 94402, USA | Website: https://www.sagimet.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

184.4M

52 Wk Range

$1.73 - $11.41

Previous Close

$5.67

Open

$5.69

Volume

829,006

Day Range

$5.63 - $6.34

Enterprise Value

57.74M

Cash

32.5M

Avg Qtr Burn

-10.18M

Insider Ownership

5.94%

Institutional Own.

40.91%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Denifanstat (ASC40) Details Acne	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat w/ Bevacizumab Details Glioblastoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Metabolic-dysfunction Associated Steatohepatitis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Non-alcoholic steatohepatitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat + Resmetirom Details Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TVB-3567 Details Acne	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Liver disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.